You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
以嶺藥業(002603.SZ):連花清瘟可與解熱鎮痛藥物「布洛芬」聯用
阿思達克 12-20 13:39
以嶺藥業(002603.SZ)繼上日跌停後,今早(20日)低開4.6%,隨後跌幅收窄,現跌1.7%,報40元人民幣。 公司隔晚(19日)在深交所互動平台表示,旗下連花清瘟可以與解熱鎮痛藥物(如布洛芬,Ibuprofen)聯用,但需重點關注是否存在解熱鎮痛藥物使用禁忌情況,在醫師指導下聯合使用。 以嶺藥業稱,一項針對112例兒童的連花清瘟和布洛芬顆粒等西藥聯合應用的臨床研究,結果顯示聯合應用與單用布洛芬顆粒西藥不良反應發生率無差異,未見肝腎功能損傷。近十年覆蓋全國18家三甲醫院應用連花清瘟的真實世界研究,顯示連花清瘟與抗感染藥、解熱鎮痛抗炎藥、祛痰止咳藥、擴張支氣管藥、保護胃黏膜藥聯合應用,療效確切,安全性良好,並未見嚴重不良反應的報道。 另有一項來自全國16家三甲等醫院的醫療信息系統數據分析顯示,連花清瘟與Paracetamol(撲熱息痛)、布洛芬、Aspirin(阿士匹靈)等藥物聯合應用,安全性良好,未見連花清瘟相關的肝腎功能損傷不良反應。目前,連花清瘟被國家中醫藥管理局《新冠病毒感染者居家指引(第一版)》,與布洛芬等西藥均列為新冠肺炎感染者居家常用藥物。 綜上,連花清瘟常規聯合解熱鎮痛藥物(如布洛芬)臨床安全性良好。同時我們可以看到,解熱鎮痛抗炎藥對Paracetamol、布洛芬等說明書均提示具有肝腎毒性,嚴重肝腎功能不全者應慎用,嚴禁過量和反覆多次使用。因此,連花清瘟與布洛芬聯合使用時,需重點關注是否存在解熱鎮痛藥物使用禁忌情況,在醫師指導下聯合使用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account